Articolul precedent |
Articolul urmator |
185 1 |
Ultima descărcare din IBN: 2023-08-26 11:45 |
Căutarea după subiecte similare conform CZU |
615.4:616.9 (1) |
Формы лекарственных средств. Медицинские материалы. Оборудование (103) |
Инфекционные заболевания. Инфекционные лихорадки (587) |
SM ISO690:2012 BRAICOV, Ana. Utilizarea preparatelor heparinei la pacienții cu infecția SARS CoV-2 .. In: Interuniversitaria, Ed. 19, 4 mai 2023, Bălți. Bălți, Republica Moldova: Universitatea de Stat „Alecu Russo" din Bălţi, 2023, Ediția 19, Vol.3, pp. 149-157. ISBN 978-9975-50-303-7.. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Interuniversitaria Ediția 19, Vol.3, 2023 |
||||||
Conferința "Interuniversitaria" 19, Bălți, Moldova, 4 mai 2023 | ||||||
|
||||||
CZU: 615.4:616.9 | ||||||
Pag. 149-157 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
The COVID-19 pandemic has caused severe health problems: acute respiratory distress syndrome and progressive alteration of some inflammatory and coagulative parameters. Heparin and low molecular weight heparin are the mostly used anticoagulant for the prevention and treatment of thrombosis, therefore have been recommended by WHO to apply to moderate-severe COVID-19 patients. He-parin and low molecular weight heparin possesses other biological activities inclu-ding anticoagulant, anti-inflammatory and direct antiviral activities, increasing the release of hepatic lipase and lipoprotein lipase, suppressing complement activa-tion, inhibiting angiogenesis, and modulating tumor progress and metastasis. |
||||||
Cuvinte-cheie COVID-19, heparin, Low molecular weight heparin, cytokine storm, thromboinflammation, coagulopathy |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-186181</cfResPublId> <cfResPublDate>2023</cfResPublDate> <cfVol>Ediția 19, Vol.3</cfVol> <cfStartPage>149</cfStartPage> <cfISBN>978-9975-50-306-8.</cfISBN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/186181</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Utilizarea preparatelor heparinei la pacienții cu infecția SARS CoV-2 .</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>COVID-19; heparin; Low molecular weight heparin; cytokine storm; thromboinflammation; coagulopathy</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>The COVID-19 pandemic has caused severe health problems: acute respiratory distress syndrome and progressive alteration of some inflammatory and coagulative parameters. Heparin and low molecular weight heparin are the mostly used anticoagulant for the prevention and treatment of thrombosis, therefore have been recommended by WHO to apply to moderate-severe COVID-19 patients. He-parin and low molecular weight heparin possesses other biological activities inclu-ding anticoagulant, anti-inflammatory and direct antiviral activities, increasing the release of hepatic lipase and lipoprotein lipase, suppressing complement activa-tion, inhibiting angiogenesis, and modulating tumor progress and metastasis.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-110979</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-110979</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-110979-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023T24:00:00</cfStartDate> <cfFamilyNames>Braicov</cfFamilyNames> <cfFirstNames>Ana</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>